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Abstract
Background Guidelines on codeine safety during pregnancy
rely on small studies with inconsistent results, and associa-
tions between codeine use during pregnancy and increased
risk of congenital malformations remain unsubstantiated.
Objectives Our objective was to analyze the effect of
codeine on pregnancy outcome.
Methods Pregnancy outcomes of 2,666 women who used
codeine during pregnancy were compared with 65,316
women who used no opioids during pregnancy. Information
on maternal sociodemographic and medical characteristics,
potential confounders, and pregnancy outcome was
obtained from The Norwegian Mother and Child Cohort
Study [den norske Mor & barn-undersøkelsen (MoBa)] data
set and the Medical Birth Registry of Norway (MBRN) data
set. The data sets were linked via the maternal personal
identification number. Associations between codeine therapy
and pregnancy outcomes were identified using logistic
regression analyses.
Results No significant differences were found in the
survival rate [adjusted odds ratio (OR) 0.9, 95% confidence
interval (CI) 0.6–1.5] or the congenital malformation rate
(adjusted OR 0.9, 95% CI 0.8–1.1) between codeine-
exposed and unexposed infants. Codeine use anytime
during pregnancy was associated with planned Cesarean
delivery (adjusted OR 1.4, 95% CI 1.2–1.7; P<0.0001).
Third-trimester use was associated with acute Cesarean
delivery (adjusted OR 1.5, 95% CI 1.3–1.8; P<0.0001) and
postpartum hemorrhage (adjusted OR 1.3, 95% CI 1.1–1.5;
P<0.0001). No significant associations with other adverse
pregnancy outcomes were found.
Conclusions No effects of maternal codeine intake during
pregnancy were observed on infant survival or congenital
malformation rate. Our findings are reassuring; however,
the association with acute Cesarean delivery and postpar-
tum hemorrhage may justify a certain level of caution when
administering codeine toward the end of pregnancy.
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Introduction
Few studies address the safety of codeine use during
pregnancy despite its extensive use as an analgesic and
antitussive in the general population. The frequency of
codeine use during pregnancy has been shown to range
between 1% and 3.5% [1–3]. Studies specifically targeting
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control studies or case reports with inherent methodological
limitations that generally warrant cautious interpretation.
No data from cohort studies are available to date. One case–
control study of 504 children with neuroblastoma found an
association with in utero exposure to codeine [odds ratio
(OR) 3.4, 95% confidence interval (CI) 1.4–8.4] [4].
Another of 599 infants found that mothers who gave birth
to infants with cleft palate or cleft lip with or without cleft
palate used opioid analgesics (mainly codeine) much more
frequently than the control group; the largest difference was
seen for codeine use during the first trimester (8.6%
compared with 2.1% of infants in the control group; P<
0.01) [5]. In a third case–control study of 1,370 infants, 12
infants with major congenital malformations had been
exposed to codeine during the first trimester compared
with seven in the control group (OR 3.7, Fisher’s one-tailed
P value 0.004) [6]. Neonatal abstinence syndrome has been
described in two cases in which codeine was used by the
mother over a period of several days close to term [7]. Two
other reports described an association between neonatal
abstinence syndrome and possibly cerebral infarction after
maternal intake of codeine close to term [8].
Evidently, most of studies and case reports focus either
on the possible teratogenicity of codeine or neonatal
abstinence syndrome. The latter has mainly been shown to
be associated with other opioids [9]. Other pregnancy
outcomes, including postpartum complications, have only
been studied in populations using opioid analgesics in
general and those of addicted pregnant women [10–12] and
not in pregnant women taking codeine in therapeutic doses.
It is likely that these studies were subject to bias due to
inclusion of populations with very specific sociodemo-
graphic and lifestyle characteristics, and the effects of
codeine use as such would thus be difficult to evaluate [10–
12]. Notwithstanding, leading literature sources on the
safety of drug use during pregnancy suggest that sporadic
use of codeine is safe except toward the end of pregnancy
[9, 13].
Using data from a large prospective cohort study, our
aim was to evaluate the potential teratogenicity of codeine
and investigate possible associations with other adverse
pregnancy outcomes that have not been studied so far.
Methods
Data for this study were retrieved from The Norwegian
Mother and Child Cohort Study [den norske Mor & barn-
undersøkelsen (MoBa)] data set (version four) released in
December 2008 and from records from the Medical Birth
Registry of Norway(MBRN). MoBa [14] is a prospective
cohort study conducted by the Norwegian Institute of
Public Health. The overall aim of the study is to examine
the effect of a vast number of exposures on pregnancy
outcome and maternal and fetal health during pregnancy
and postpartum. Data were obtained from three self-
administered questionnaires answered by pregnant women
who participated in the study between 1999 and 2006.
Pregnant women received a postal invitation with an
informed consent form and the first questionnaire prior to
their first ultrasound scan during gestational weeks 17 or
18. This first questionnaire covered the time period between
the 6 months prior to pregnancy and the 18th gestational
week. The second questionnaire covered the time period
between the 19th and 29th gestational week, and the third
questionnaire covered the time period from the 30th
gestational week until birth. The questionnaires covered
sociodemographic and lifestyle data, maternal medical
history, maternal health during the pregnancy, drug use,
and neonatal health. The overall response rate was 43.5%
[15]. The MBRN [16] encompasses all births in Norway
and has been prospectively collecting data on all deliveries
since 1967. Approximately 60,000 infants are born in
Norway every year, corresponding to an annual birth rate of
1.2 infants per 100 inhabitants. Data stem from mandatory
standardized forms filled out by midwives, obstetricians,
and/or pediatricians at each delivery and from the mother’s
pregnancy medical records. The standardized forms cover
sociodemographic and lifestyle information on the mother
and medical information including maternal health prior to
and during pregnancy as well as delivery and postpartum
complications and interventions. Data from the two sources
were linked via the woman’ personal identification number,
which is assigned to every legal resident in Norway. The
study was approved by the Regional Committee for Ethics
in Medical Research, Region South, and the Norwegian
Data Inspectorate.
Study population
The original quality-assured data file released for research
in 2008 (version 4) consisted of data on 72,934 women. All
these women had a pregnancy outcome registered in the
MBRN. Prior to release of this data file, 3.5% of the
women in the study did not have a pregnancy outcome
registered, mainly due to spontaneous abortions that
happened early on in pregnancy. Of the 72,934 women,
3,005 who did not complete the first questionnaire were
excluded. A total of 69,929 pregnant women with records
both in both data sets were eligible for inclusion (95.9% of
the original data file). In addition, women using opioids
other than codeine (i.e., ethylmorphine, morphine, ketobe-
midone, tramadol, pethidine, dextropropoxyphene, oxy-
codone, buprenorphine, and methadone) (n=1,664) and
women using both codeine and one or several of the
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study population therefore consisted of 67,982 women
(93.2% of the original data file). Multiple pregnancies were
included; however, only data on the first-born infant were
used, as only these were linked to maternal data.
Explanatory variables
Explanatory variables consisted of the following subsets: (i)
pregnant women who used codeine (alone or in a fixed
combination with paracetamol) during pregnancy (total)
(yes/no); (ii) pregnant women who used codeine (alone or
in a fixed combination with paracetamol) during the first
trimester (gestational weeks 0–12) (yes/no); (iii) pregnant
women who used codeine (alone or in a fixed combination
with paracetamol) during the second trimester (gestational
weeks 13–28) (yes/no); (iv) pregnant women who used
codeine (alone or in a fixed combination with paracetamol)
during the third trimester (gestational week 29 until
delivery) (yes/no). Drug therapy was classified and grouped
according to the Anatomical Therapeutic Chemical (ATC)
classification system developed by the World Health Organi-
zation (WHO) [17]. ATC codes used were R05DA04
(codeine alone) and N02AA59 (codeine in a fixed combi-
nation with paracetamol). Codeine in fixed combinations
with acetylsalicylic acid or other nonsteroidal antiinflamma-
tory drugs is not available in Norway. The explanatory
variable subsets were created using answers to questions
regarding both codeine use and maternal illness in ques-
tionnaires one and two as long as the ATC code for codeine
and the timing of either codeine use or the medical condition
was specified. Subanalyses were performed to investigate
possible associations between the extent of codeine use
(number of days used, categorized as 1–7d a y s ,8 –14 days,
and >14 days) and pregnancy outcome.
Confounding factors
Confounding factors included sociodemographic, lifestyle,
and medical characteristics (Tables 1 and 2), concomitant
drug use (Table 3) (this information was derived from
theMoBa questionnaires), and factors related to delivery
(this information was derived from the MBRN). Different
potential confounding factors, the majority of which are
listed in Tables 1–4 were selected for each pregnancy
outcome. (Please find the complete list of confounding
factors used in the analyses in Electronic supplementary
material (ESM) 1: Confounding factors.)
Outcome variables
Outcome variables were retrieved from both MoBa and
MBRN. The choice of outcome variables was based on
current information on codeine safety during pregnancy and
studies on the effect of opioid analgesics on pregnancy
outcome and labor progress, with special focus on
prolonged labor and neonatal complications. The chosen
variables consisted of any congenital malformations
detected at birth, major congenital malformations detected
at birth, survival (live birth, miscarriage/stillbirth, perinatal
death, death during the first 12 months of life), birth weight
<2,500 g, gestational age <37 weeks, Apgar scores <7 at 1
and 5 min, neonatal respiratory depression, neonatal
hypoglycemia, newborn admitted to intensive care unit,
acute Cesarean delivery, planned Cesarean delivery, atonic
uterus, prolonged labor, and postpartum hemorrhage
>500 ml. All outcome variables were dichotomized into
yes or no categories.
Statistical analysis
Logistic regression analyses were performed to identify
significant associations between codeine therapy and
pregnancy outcome. Subsets of confounding factors were
selected for each pregnancy outcome depending on clinical
plausibility, statistical significance, and size of outcome
event rates (a full list of confounding factors controlled for in
each analysis is available in the ESM 1: Confounding
factors). Confounding factors controlled for in logistic
regression analyses were chosen on the basis of theoretical
clinical significance and initial Pearson’s χ
2 analyses, where
the P value was <0.25. Preliminary logistic regression
analyses enabled the subsequent removal of potential
confounding variables, with a P value of >0.5, with the
exception of instances in which the coefficient change of the
exposure variable was >20%. The final logistic regression
models for pregnancy outcome included statistically signifi-
cant variables and clinically plausible interactions only. The
threshold for retaining these variables in the final logistic
regression model was P<0.05. Potential multicollinearity
among the independent variables was identified using
multiple regression analysis. Tolerance values for multi-
collinearity were set at >0.5. Hosmer and Lemeshow
goodness-of-fit tests >0.5 indicated robust models and were
considered valid in the logistic regression analyses. All
statistical analyses were performed with the Statistical
Package for Social Sciences SPSS for Windows version
16.1 (SPSS, Chicago, IL, USA). Risk ratio estimates are
given as odds ratios (OR) with 95% confidence intervals (CI).
Results
Of the 67,982 pregnant women in the study, 2,666 (3.9%)
used codeine during pregnancy (exposed group), whereas
65,316 (96.1%) did not (unexposed group). In the exposed
Eur J Clin Pharmacol (2011) 67:1253–1261 1255group, 45 women used codeine alone and 2,621 used codeine
in a fixed combination with paracetamol. A higher proportion
of exposed women had attained lower levels of education,
were not married or cohabiting with their partner, were
overweight (had a body mass index >25 kg/m
2)p r i o rt o
pregnancy, and smoked throughout pregnancy (Table 1).
Moreover, these women were more likely to suffer from
medical complications both prior to and during pregnancy
(Table 2). Concomitant nonsteroidal antiinflammatory drug
and psychotropic agent use was also significantly higher in
the exposed group than in the unexposed group (Table 3).
No significant difference was found in the survival rate of
infants when comparing the exposed (99.4% live births) with
the unexposed (99.2% live births) groups (adjusted OR 0.9,
95% CI 0.6–1.5] (Table 4). No significant difference in
overall congenital malformation rate was found when
comparing the exposed (4.9%) with the unexposed (5.0%)
group (adjusted OR 0.9, 95% CI 0.8–1.1). No significant
difference in the major congenital malformation rate was
found between the exposed (2.9%) and unexposed (2.9%)
group (adjusted OR 0.9, 95% CI 0.7–1.2) (Table 4).
Codeine use anytime during pregnancy was significantly
associated with an increased risk of acute Cesarean delivery
(12.8% in the exposed group compared with 8.9% in the
Table 1 Maternal characteristics of the study population
Women who used codeine during
pregnancy; exposed group (n=2,666)
Women who did not use opioids during
pregnancy: unexposed group (n=65,316)
No. % No. %
Maternal age (years)
< 20 32 1.2 714 1.1
20 – 29 1,194 44.8 28,840 44.1
30 – 39 1,380 51.8 34,530 52.9
≥ 40 60 2.2 1,234 1.9
Parity
0 1,153 43.2 28,523 43.7
≥1 1,513 56.7 36,787 56.3
Plurality
1 2,611 97.9 64,123 98.2
> 1 55 2.1 1,193 1.8
Ethnicity
Of Norwegian descent 2,572 96.5 61,782 94.6
Not of Norwegian descent 94 3.5
* 3,534 5.4
Marital status
Married/cohabiting 2,553 95.8 63,484 97.2
Other 113 4.2
* 1,832 2.8
Education
Primary 80 3.0 1623 2.5
Secondary 1,005 37.7 20,803 31.8
Tertiary 1,525 57.2
* 41,607 63.4
BMI prior to pregnancy (kg/m
2)
< 18.5 65 2.4 2,002 3.1
18.5 – 25.0 1,479 55.5 41,930 64.2
> 25.0 1,050 39.4
* 19,483 29.8
Folic acid intake prior to pregnancy 596 22.3 15,041 23.0
Sick leave lasting longer than 2 weeks during pregnancy 1,023 38.4
* 20,505 31.4
Smoking at gestational week 30 391 14.7
* 6,180 9.4
Alcohol intake during pregnancy
a 1,421 53.3
** 3,3512 51.3
Some data do not add up to the total due to missing values
* Pearson’s χ
2 test P<0.001 when compared with the unexposed control group,
** Pearson’s χ
2 test P<0.05 when compared with the unexposed control group
a Including data on sporadic intake and intake before the women were aware of their pregnancy
1256 Eur J Clin Pharmacol (2011) 67:1253–1261unexposed group) (adjusted OR 1.3, 95% CI 1.1–1.5),
planned Cesarean delivery (7.4% in the exposed group
compared with 5.0% in the unexposed group) (adjusted OR
1.4, 95% CI 1.2–1.7), and postpartum hemorrhage (18.3% in
the exposed group compared with 14.5% in the unexposed
group) (adjusted OR 1.2, 95% CI 1.1–1.4) (Table 4).
Upon analyzing the effects of codeine on pregnancy
outcome during the three specific trimesters, an increased
risk of planned Cesarean delivery was seen after exposure
in the first (7.3%; adjusted OR 1.4, 95% CI 1.1–1.7),
second (7.5%; adjusted OR 1.5, 95% CI 1.2–1.8), and third
(8.9%; adjusted OR 1.6, 95% CI 1.3–2.0) trimesters. Third
Table 2 Maternal health and pregnancy complications
Women who used codeine during
pregnancy: exposed group (n=2,666)
Women who did not use opioids during
pregnancy: unexposed group (n=65,316)
No. % No. %
Maternal health during pregnancy
Acute musculoskeletal pain 2,534 95.0
* 58,005 88.8
Migraine and/or headache 1,536 57.6
* 23,115 35.4
Proteinuria 766 28.7
* 13,262 20.3
Temperature>38.5°C fever associated with a rash 590 22.1
* 10,453 16.0
Hospitalization
** 270 10.1
* 2,839 4.3
Urinary tract infection and/or pyelonephritis 258 9.7%
***a 5,371 8.2
Preeclampsia and/or eclampsia 157 5.9
* 2,592 4.0
Involved in an accident 122 4.7
* 2,003 3.1
High blood pressure during the first trimester
a 65 2.4
* 998 1.5
Maternal health prior to pregnancy
Musculoskeletal pain (any) 1,892 71.0
* 34,562 52.9
Arthritis/Systemic Lupus Erythematosus/
Fibromyalgia
348 13.0
* 2,504 3.8
Depression 258 9.7
* 3,533 5.4
Asthma 190 7.1
* 2,885 4.4
Cardiac disease 140 5.2
* 2,108 3.2
Thyroid disorder 70 2.6
**** 1,293 2.0
Diabetes (type I or II) 44 1.6 810 1.2
Obstetric complications
Number of ultrasound examinations
< 2 462 17.3 15,491 23.7
2 – 4 1,255 47.1 30,366 46.5
> 5 650 24.3
* 10,205 15.6
Vaginal bleeding during pregnancy
b 601 22.5
* 11,979 18.3
First trimester 498 18.7
* 10,027 15.3
Second and/or third trimesters 226 8.5
* 4,295 6.6
Oligohydramnios 62 2.3 1,506 2.3
Placenta previa 46 1.7
**** 821 1.3
Polyhydramnios 32 1.2 556 0.8
Abruptio placentae 17 0.6 271 0.4
*Pearson’s χ
2 test P<0.001 when compared with the unexposed control group,
**Excluding hospitalization due to vaginal bleeding and high blood pressure,
***Pearson’s χ
2 test P<0.01 when compared with the unexposed control group
****Pearson’s χ
2 test P<0.05 when compared with the unexposed control group.
aDefined as systolic blood pressure≥140 mmHg
bVaginal bleeding lasting more than 1 day or of an amount exceeding a trace or two or more episodes of bleeding or vaginal bleeding which has
led to hospitalization
Eur J Clin Pharmacol (2011) 67:1253–1261 1257trimester use was, in addition, associated with an increased
risk of acute Cesarean delivery (15.1%; adjusted OR 1.5,
95% CI 1.3–1.8) and postpartum hemorrhage (20.3%;
adjusted OR 1.3, 95% CI 1.1–1.5) (Table 4). Subanalyses
on the effect of codeine therapy duration on pregnancy
outcomes revealed that codeine use lasting >14 days was
significantly associated with planned (but not acute)
Cesarean delivery (unadjusted OR 3.2, 95% CI 1.3–7.9).
No dose–effect relationship was found for postpartum
hemorrhage.
Discussion
Information on the safety of analgesic use during pregnancy
is an important issue for all clinicians prescribing these
drugs to pregnant women. It is often not feasible to
prescribe the more thoroughly documented nonopioid
analgesics either for safety reasons or lack of adequate
pain relief. The safety profiles of as many different
analgesics as possible must be known before an individual
risk–benefit evaluation can be done. In this study, codeine
use during pregnancy was not found to be associated with
infant survival rate, congenital malformation rate, or other
adverse pregnancy outcomes, except for Cesarean delivery
and excessive postpartum hemorrhage. Unlike previous
studies [4, 5, 7, 8] and other medical literature sources that
rely either on data regardng opioid analgesic use in general
or a few case studies [9, 13], we found no increased risk of
congenital malformations or neonatal respiratory depres-
sion. Associations of codeine use during pregnancy and
neonatal abstinence syndrome were unfortunately not
feasible to evaluate, as neonatal abstinence syndrome
scores were not routinely applied. However, neither low
Apgar scores nor admission of the neonate to intensive care
were associated with codeine use during pregnancy, and
these outcomes are also partly representative of neonatal
abstinence syndrome.
Of other adverse pregnancy outcomes, the strongest
association was between codeine use during pregnancy and
increased risk of planned Cesarean delivery. This associa-
tion remained significant, even after controlling for several
clinically and statistically significant potential confounders,
including high birth weight, fetal malpresentation, plurality,
placenta previa, and others (a full list is available in the
ESM 1: Confounding factors). A dose–effect relationship
between codeine and planned Cesarean delivery was also
detected. Nevertheless, we believe it is highly likely that the
association was due to underlying medical conditions.
Thirteen percent of exposed women suffered from chronic
conditions, including arthritis, systemic lupus erythemato-
sus, and fibromyalgia, compared with only 3% in the
unexposed group; almost 10% had depression compared
with only 5% of the unexposed women; a significantly
Table 3 Frequency of concomitant nonsteroidal antiinflammatory drug and psychotropic agent use during pregnancy
Drug Women who used codeine during
pregnancy: exposed group (n=2,666)
Women who did not use opioids during
pregnancy: unexposed group (n=65,316)
No. % No. %
NSAIDs 759 28.5
* 8,271 12.6
Ibuprofen 470 17.6
* 6,269 9.6
Diclofenac 170 6.4
* 703 1.1
Naproxen 85 3.2
* 782 1.2
Other
a 185 6.9
* 1,323 2.0
Psychotropic agents 359 13.5
* 3,159 4.8
Antidepressants
b 172 6.4
* 1,935 3.0
Anxiolytics
c 132 4.9
* 788 1.2
Hypnotics
d 86 3.2
* 490 0.7
Antipsychotics
e 60 2.2
* 452 0.7
NSAIDS nonsteroidal anti-inflammatory drugs
*Pearson’s χ
2 test P<0.001 when compared with the unexposed control group
aIncluding piroxicam, meloxicam, indomethacin, acetylsalicylic acid, ketoprofen, nabumetone, and tolfenamic acid
bIncluding selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, mianserin, mirtazapine, and
venlafaxine
cIncluding diazepam, oxazepam, alprazolam, hydroxyzine, and buspirone
dIncluding nitrazepam, flunitrazepam, zopiclone, and zolpidem
eIncluding levomepromazine, perphenazine, prochlorperazine, flupenthixol, zuclopenthixol, olanzapine, quetiapine, and risperidone
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Eur J Clin Pharmacol (2011) 67:1253–1261 1259higher number of exposed women had asthma and
cardiac disease; about 10% were hospitalized during
pregnancy compared with 4% of the unexposed group;
and 5.9% had preeclampsia and/or eclampsia compared
with 4% of the unexposed group. Several of these
diseases and conditions, which were not feasible to
control for in this particular analysis, are associated with
planned Cesarean delivery [18]. Association codeine
therapy duration may also be indicative of the severity of
the underlying medical conditions.
Notwithstanding, we cannot definitively exclude a
direct association between codeine and acute Cesarean
delivery and postpartum hemorrhage. A study on
315,085 pregnancies concluded that preeclampsia was
significantly associated with postpartum hemorrhage and
postulated that a deprivation of angiogenic factors
resulting in the preeclamptic state may also play a role
in postpartum hemorrhage [19]. It is also known that
opioid analgesics administered during labor in the form of
epidural analgesia are implicated in uterine atony [20, 21].
Failure or weakening of myometrial contractions may
result in excessive postpartum hemorrhage as well as
Cesarean delivery [18]. However, atonic uterus and
prolonged labor, cesarean delivery, induction of labor,
epidural analgesia, third- or fourth-grade perineal tears and
high birth weight, preeclampsia and/or eclampsia, placenta
previa, and abruptio placentae, among others (a full list is
available in the ESM 1: Confounding factors), were all
controlled for in our analyses. It should be noted that the
vast majority of women (98.3%) in the exposed group
used codeine in a fixed combination with paracetamol.
However, we found no evidence of a possible association
between paracetamol and increased risk of acute Cesarean
delivery or postpartum hemorrhage.
Several study strengths and limitations merit specific
attention. Our study is the only prospective cohort study on
codeine use during pregnancy. Information derived from
both MoBa and NMBR provided us with an extensive array
of medical and sociodemographic characteristics of the
study population. This enabled us to control for a very large
number of—but not all—important confounding factors.
Several validity studies concluded that the accuracy of
registration of major congenital malformations is satisfac-
torily high [22, 23]. The prospective collection of the
majority of data greatly reduced the risk of recall bias.
Differential reporting by the pregnant women was also
avoided, as their pregnancy outcome was unknown to most
of them at the time of data collection. In contrast to many
other large studies, the chances of obtaining false positive
associations due to multiple testing were reduced by
including a minimum number of cases (more than four) in
the final analysis. Moreover, all associations that were
statistically significant had P values <0.0001. On the other
hand, a difference in the prevalence of drug use and
pregnancy outcomes in the study population compared with
the general population may have occurred, as participant
response rate was only 43.5%. However, it has been shown
that only minor differences (<2% in absolute differences in
sociodemographic variables) between MoBa participants
and the general population of pregnant women exist, and no
differences in the estimates of association measures were
found between participants and the general population [15,
24]. Despite this, the risk of false negative associations due
to underrepresentation of certain sociodemographic groups,
possible underreporting of codeine use during pregnancy,
and the rarity of some pregnancy outcomes such as major
malformations, should be taken into account. Analyses on
specific malformations could not be undertaken due to low
statistical power. It was also not feasible to determine the
codeine dose pregnant women used and the exact point in
time it was taken.
In conclusion, the fact that codeine use during pregnancy
h a dn oe f f e c to ni n f a n ts u r v i v a lo rc o n g e n i t a lm a l f o r m a t i o n
rate is particularly reassuring considering the size and
singularity of this cohort study and the accuracy of pregnancy
outcome reporting. We found an association between codeine
use anytime during pregnancy and planned Cesarean delivery
and between third-trimester codeine use and acute Cesarean
delivery and excessive postpartum hemorrhage. Whereas the
increased risk of Cesarean delivery, in particular, may be
caused by underlying medical conditions, a direct association
between codeine use toward the end of pregnancy and acute
Cesarean delivery and postpartum hemorrhage cannot be
definitively excluded.
Grants The Norwegian Mother and Child Cohort Study is
supported by the Norwegian Ministry of Health and the Ministry of
Education and Research, NIH/NIEHS (contract no NO-ES-75558),
NIH/NINDS (grant No.1 UO1 NS 047537–01), and the Norwegian
Research Council/FUGE (grant no.151918/S10). We are grateful to all
participants and their families for taking part in this study.
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Andrade S, Gurwitz J, Davis R, Chan A, Finkelstein J, Fortman K et
al (2004) Prescription drug use in pregnancy. AJOG 191:398–407
1260 Eur J Clin Pharmacol (2011) 67:1253–12612. Rubin J, Ferencz C, Loffredo C, The Baltimore-Washington Infant
Study Group (1993) Use of prescription and non-prescription
drugs in pregnancy. J Clin Epidemiol 46:581–589
3. EngelandA,BramnessJ,DaltveitA,RønningM,SkurtveitS,FuruK
(2008) Prescription drug use among fathers and mothers before and
during pregnancy. A population-based cohort study of 106 000
pregnanciesinNorway2004–2006.BrJClinPharmacol65:653–660
4. Cook M, Olshan A, Guess H, Savitz D, Poole C, Blatt J et al
(2004) Maternal medication use and neuroblastoma in offspring.
Am J Epidemiol 159:721–731
5. Saxen I (1975) Associations between oral clefts and drugs taken
during pregnancy. Int J Epidemiol 4:37–44
6. Bracken M, Holford T (1981) Exposure to prescribed drugs in
pregnancy and association with congenital malformation. Obstet
Gynecol 58:336–344
7. Mangurten H, Benawra R (1980) Neonatal codeine withdrawal in
infants of nonaddicted mothers. Pediatrics 65:159–160
8. Reynolds E, Riel-Romero R, Bada H (2007) Neonatal abstinence
syndrome and cerebral infarction following maternal codeine use
during pregnancy. Clin Pediatr 46:639–645
9. Schaefer C, Peters P, Miller RK (2007) Drugs during pregnancy
and lactation. Elsevier, Amsterdam
10. Mayet S, Groshkova T, Morgan L, Maccormack T, Strang J (2008)
Drugs and pregnancy - outcomes of women engaged with a
specialist perinatal outreach addictions service. Drug Alcohol Rev
27:497–503
11. Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK
(2009) Risk factors for preterm birth among opiate-addicted
gravid women in a methadone treatment program. Am J Obstet
Gynecol 201:326.e1–6
12. Vucinovic M, Roje D, Vucinovic Z, Capkun V, Bucat M, Banovic
I (2008) Maternal and neonatal effects of substance abuse during
pregnancy: our ten-year experience. Yonsei Med J 49:705–713
13. Briggs G, Freeman R, Yaffe S (2005) Drugs in pregnancy and
lactation. Lippincott Williams & Wilkins, Philadelphia
14. Norwegian Institute of Public Health (2010) The Norwegian
Mother and Child Cohort Study. Oslo, Norway
15. Nilsen R, Vollset S, Gjessing H, Skjærven R, Melve K, Schreuder
P et al (2009) Self-selection and bias in a large prospective
pregnancy cohort in Norway. Paediatr Perinat Epidemiol 23:597–
608
16. Norwegian Institute of Public Health (2010) Medisinsk fødselsregister.
Oslo, Norway
17. WHO Collaborating Centre for Drug Statistics Methodology.
ATC/DDD Index 2008
18. Leveno KJ, Cunningham FG, Alexander JM, Bloom SL, Casey
BM, Dashe JS et al (2007) Williams manual of obstetrics:
Pregnancy complications. McGraw-Hill, New York
19. Eskild A, Vatten LJ (2009) Abnormal bleeding associated with
preeclampsia: a population study of 315,085 pregnancies. Acta
Obstet Gynecol Scand 88:154–158
20. Liu EHC, Sia ATH (2004) Rates of caesarean section and
instrumental vaginal delivery in nulliparous women after low
concentration epidural infusions or opioid analgesia:systematic
review. BMJ 329:293–298
21. Kjærgaard H, Olsen J, Ottesen B, Nyberg P, Dykes A-K (2008)
Obstetric risk indicators for labour dystocia in nulliparous
women: a multi-centre cohort study. BMC Pregnancy Child-
birth 8:1–8
22. Melve K, Lie R, Skjærven R, Van Der Hagen C, Gradek G,
Jonsrud C et al (2008) Registration of Down syndrome in the
Medical Birth Registry of Norway: validity and time trends. Acta
Obstet Gynecol Scand 87:824–830
23. Kubon C, Sivertsen A, Vindenes H, Abyholm F, Wilcox A, Lie R
(2007) Completeness of registration of oral clefts in a medical
birth registry: a population-based study. Acta Obstet Gynecol
Scand 86:1453–1457
24. Magnus P, Irgens L, Haug K, Nystad W, Skjærven R, Stoltenberg
C et al (2006) Cohort profile: The Norwegian mother and child
cohort study (MoBa). Int J Epidemiol 35:1146–1150
Eur J Clin Pharmacol (2011) 67:1253–1261 1261